Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Januar 2018

Planlagt Fastgjort Låst Flyttet Genmab
2.4k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • M Offline
    M Offline
    Mcjean
    wrote on sidst redigeret af
    #976

    Helt enig Stockbull, Genmabs andre stoffer end lige Dara og Ofa burde jo have en forventet pris, men næh nej det bliver for kompliceret, derfor kan jeg ikke tage analytikerne seriøse........der er noget helt galt med kursen.

    1 Reply Last reply
    0
    • S Offline
      S Offline
      Stocking
      wrote on sidst redigeret af
      #977

      Er det her nogle af jer ved om kan betyde noget: https://videnskab.dk/krop-sundhed/crispr-krise-immunforsvaret-kan-knuse-verdens-store-genteknologiske-haab

      1 Reply Last reply
      0
      • S Offline
        S Offline
        Stocking
        wrote on sidst redigeret af
        #978

        Overskriften er: CRISPR-krise: Immunforsvaret truer verdens store genteknologiske håb

        1 Reply Last reply
        0
        • P Offline
          P Offline
          Parasitism
          wrote on sidst redigeret af
          #979

          Mcjean - tror det er den generelle udfordring for mange bio aktier. Det er for kompliceret for alm. mennesker at forstå de komplekse medicin faglige aspekter. Vi kan så hurtigt være enig om at analytikerne og de store fonde burde kunne gennemskue potentialet. Dog må man jo nok også være bål- pisser og erkende, at aktien har noget gemt værdi, men at kursen altid vil være hvad folk vil betale for den.

          1 Reply Last reply
          0
          • M Offline
            M Offline
            Mcjean
            wrote on sidst redigeret af
            #980

            Enig! Men tror ikke de store fonde kan eller vil gå markant ind i en aktie i biotek uden at det har materialiseret sig til en vis grad og kan derfor ikke klandres for den lave pris, tror de har retningslinjer der forbyder dem mere end et vist antal. Hvis salget var 5bn$ så ville der nok komme en værdisætning af andre stoffer i pipelinen, men indtil da må vin ok bare acceptere små stigninger indtil salget når et vis punkt.

            1 Reply Last reply
            0
            • M Offline
              M Offline
              Mcjean
              wrote on sidst redigeret af
              #981

              Min computer er ufattelig ringe til at læse korrektur.

              1 Reply Last reply
              0
              • N Offline
                N Offline
                NiklasZ
                wrote on sidst redigeret af
                #982

                Er der en, der har et link til ROIs analyse?

                1 Reply Last reply
                0
                • S Offline
                  S Offline
                  Sukkeralf
                  wrote on sidst redigeret af
                  #983

                  Ligger i debatten

                  1 Reply Last reply
                  0
                  • S Offline
                    S Offline
                    Sukkeralf
                    wrote on sidst redigeret af
                    #984

                    Stocking - det betyder ikke noget for Genmab

                    1 Reply Last reply
                    0
                    • S Offline
                      S Offline
                      Sukkeralf
                      wrote on sidst redigeret af
                      #985

                      Just a moment...

                      favicon

                      (www.firstwordpharma.com)

                      1 Reply Last reply
                      0
                      • S Offline
                        S Offline
                        Sukkeralf
                        wrote on sidst redigeret af
                        #986

                        Ved ikke om det kræver særlig adgang, men ellers lige et klip derfra:

                        1 Reply Last reply
                        0
                        • S Offline
                          S Offline
                          Sukkeralf
                          wrote on sidst redigeret af
                          #987

                          Final thoughts
                          While CRISPR Therapeutics is relatively insulated from immunogenicity concerns, Editas is diving into in vivo gene therapy straight away with its retinal disease programme.

                          1 Reply Last reply
                          0
                          • S Offline
                            S Offline
                            Sukkeralf
                            wrote on sidst redigeret af
                            #988

                            At a JPM presentation on January 10, Editas CEO Katrine Bosley said the company has "successfully tackled all the translation science questions" that come along with clinical development, including immunogenicity- implying that getting ahead of the issues presented by the manuscript is simply a standard part of translational science. Kulkarni had the same sentiment, saying that "in any therapeutic development, you do immunogenicity testing anyway…I think the concerns are overblown."

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Stocking
                              wrote on sidst redigeret af
                              #989

                              Tak Sukkeralf. Min tanke var mest om det var en fordel for Genmab at andre teknologiers udvikling blev forsinket.

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #990

                                You must have a lot of respect for Dara if you put this in your company update: "I-MAB’s head of R&D was formerly responsible for the clinical development of Daratumumabin China as Janssen China’s head of development" Morphosys p12 https://www.morphosys.de/sites/default/files/presentations/180110_mor_company_udate_talk_jpm_final.pdf

                                1 Reply Last reply
                                0
                                • P Offline
                                  P Offline
                                  Plimsoller
                                  wrote on sidst redigeret af
                                  #991

                                  Er det senest den 21. FDA skal komme tilbage med priority review eller ej?

                                  1 Reply Last reply
                                  0
                                  • M Offline
                                    M Offline
                                    Mcjean
                                    wrote on sidst redigeret af
                                    #992

                                    yep men kommer den 19

                                    1 Reply Last reply
                                    0
                                    • P Offline
                                      P Offline
                                      Plimsoller
                                      wrote on sidst redigeret af
                                      #993

                                      Det håber vi på. Tak skal du have.

                                      1 Reply Last reply
                                      0
                                      • V Offline
                                        V Offline
                                        Vitus
                                        wrote on sidst redigeret af
                                        #994

                                        Igen en dårlig Genmab dag -:(

                                        1 Reply Last reply
                                        0
                                        • G Offline
                                          G Offline
                                          GeorgeBest
                                          wrote on sidst redigeret af
                                          #995

                                          Året startede i 1029. Indtil nu op med 10,3% på året. Rigtig god start på året for Genmab 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger